NorthStar Medical Radioisotopes has been successful in routinely producing non-carrier-added Actinium-225 (Ac-225) using its electron accelerator-based technology, becoming the first in the industry to do so, the company announced recently.

According to a release, Ac-225 is demonstrating a high radionuclidic purity profile, ensuring consistent performance in drug product radiolabeling and clinical development.

“Being first-to-market with routine, commercial-scale production of Ac-225 using electron-accelerator technology demonstrates the strength of NorthStar’s innovative approach and builds on our commitment of delivering high-quality radiopharmaceutical materials,” NorthStar President and CEO Dr. Frank Scholz said in a statement.

In addition, the biotech company has partnered with Convergent Therapeutics, a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals, for the treatment of cancer.

According to the partnership, Convergent will support its drug development and clinical batch production with dedicated manufacturing suites on NorthStar’s Beloit campus.

“We are pleased to expand our partnership with Convergent,” Scholz said in a statement. “This agreement underscores the value of our integrated campus designed to reduce complexity and create a robust, reliable supply chain to deliver patient-ready drugs.”